ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

ACADIA Pharma reports robust Q3 earnings and outlines growth strategies

ACADIA Pharma's Q3 earnings reflect strong sales performance, a robust financial position, and a focus on advancing its pipeline assets for future growth.
The company's new CEO brings industry expertise and a vision for expansion, while challenges in market expansion and competition require strategic planning.
Opportunities for ACADIA Pharma lie in international expansion, pipeline development, and continued efforts to drive growth through effective commercial strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

SAN DIEGO, Sept. 5, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc.

(ACAD) Alert: Johnson Fistel Announces Shareholder Class Action Against ACADIA Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound?

Digital Turbine

Big 5 Sporting Goods

Spot the best cheap stocks to buy under $5 with the right catalyst at the right time, and it could lead to your next double-digit opportunity.
The post 3 Cheap Stocks to Buy for Under $5 Now appeared first on InvestorPlace.

3 Cheap Stocks to Buy for Under $5 Now

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr.

ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.

ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio

SAN DIEGO & FORT WORTH, Texas--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain.

ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m.

ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2020.

ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results

San Diego, California--(Newsfile Corp. - July 31, 2020) -  If you would like to discuss your legal rights email leo@barrlaw.com or call (619) 780-3993.

SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)

SANTA MARIA, Calif. & SAN DIEGO--(BUSINESS WIRE)---- $ACAD--Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc.

SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)

WASHINGTON & ATLANTA & SAN DIEGO--(BUSINESS WIRE)--UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of dementia-related psychosis on more than 200 patients to better understand the patient-centered experience of symptoms and unmet treatment needs.

People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?

Alexion Pharma

Novocure

The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined - as Covid-19 impacts sectors that require a close person to person contact, companies working on Covid-19 vaccines have outperformed significantly.

Alexion, Novocure, ACADIA: Out Of Favor Health Care Stocks Poised For Gains

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 5, 2020, after the close of the U.S.

ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

Acadia Pharmaceuticals said Tuesday its experimental depression treatment failed in a Phase 3 study — prompting ACAD stock to plunge. That put shares near their lowest point this month.

Acadia Pharma Dives On Unexpected Flop In Depression Treatment

CytoSorbents

Genworth Financial

Hibbett Sports

Limelight Networks

New Age Beverages

Qiwi

Tonix Pharmaceuticals Hld

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID-19 pandemic.

9 Stocks With Massive Moves in Monday’s After-Hours Session

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S.

ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD).

ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder

Acadia Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stock Upgrades: Acadia Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Acadia Pharmaceuticals Shows Rising Relative Strength

With the three sNDA approvals in the next three years, the share price is set to soar.

Acadia Pharmaceuticals: Evaluating The Upcoming Opportunities

Y-Mabs Therapeutics Inc

While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.

2 Biotech Stocks With Major Incoming Catalysts

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Hosts 2020 Annual Meeting of Stockholders (Transcript)

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

News for ACADIA Pharma Stock (ACAD)